Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
DIAB, ADI
One or more keywords matched the following items that are connected to DIAB, ADI
Item TypeName
Academic Article A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling
Academic Article Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.
Academic Article A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling.
Academic Article Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.
Academic Article Diverse types of dermatologic toxicities from immune checkpoint blockade therapy.
Academic Article Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
Academic Article Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.
Academic Article Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
Academic Article Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis.
Academic Article Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
Concept Ipilimumab
Academic Article Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses.
Academic Article Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy.
Academic Article Conserved Interferon-? Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.
Academic Article Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.
Academic Article Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.
Academic Article Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.
Academic Article Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit.
Academic Article Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.
Academic Article Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
Search Criteria
  • Ipilimumab